Comparative analysis of adjuvant treatment outcomes in stage III endometrial cancer: overall survival, recurrence-free survival, site of primary recurrence, and toxicity
- 22 August 2025
- journal article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (11) , 102119
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic SubtypeJAMA Oncology, 2022
- A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based studyEuropean Journal of Cancer, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- FIGO stage IIIC endometrial carcinoma: Prognostic factors and outcomesGynecologic Oncology, 2009
- Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancerGynecologic Oncology, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: A retrospective studyGynecologic Oncology, 2006
- Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancerGynecologic Oncology, 2006